Akeso,Inc_德赢vwin官网ac德赢vwin【官方合作伙伴】 Akeso,Inc_德赢vwin官网ac德赢vwin【官方合作伙伴】
24.05.2021
AKESO PENPULIMAB MONOCLONAL ANTIBODY (PD-1) SUBMITTED BLA IN THE UNITED STATES
20.05.2021
LATEST UPDATES ON THE CLINICAL TRIALS OF 德赢, AK112, AK117 AND 官网 PUBLISHED AT ASCO 2021
18.05.2021
CD47 MONOCLONAL ANTIBODY (AK117) OBTAINED APPROVAL FOR PHASE I/II CLINICAL TRIAL FOR TREATMENT OF MEDIUM- TO HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
Who We Are?
About Us

Akeso,Inc. (HKEX Code: 9926.HK) is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. The Company dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. Akeso’s vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients worldwide.
 
The Company’s business is designed to drive success through both efficient and breakthrough R&D innovation. Since its inception, the Company has had the foresight to develop an end-to-end platform, Akeso Comprehensive Exploration platform (“ACE Platform”), encompassing comprehensive drug discovery and development functionalities, including target validation, antibody drug discovery and development, CMC, and GMP-compliant manufacturing...

Collaborations
Foreign cooperation

If you have any products or opportunities to cooperate and develop with us

图层 0 (4) logo图层 2 (1) logo图层 1 (1) logo图层 3 (1) logo图层 4 (1) logo
Pipelines
Product pipeline

We have One of the richest and most diversified innovative antibody drug pipeline in China

组 6 (2) logo
澳博集团官方网站载龙8国际官方网站苹果手机版新万博体育官网网站